Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Neurotrauma ; 20(6): 559-69, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12906740

RESUMO

Closed head injury often has a devastating outcome, partly because the insult, like other injuries to the central nervous system (CNS), triggers self-destructive processes. During studies of the response to other CNS insults, it was unexpectedly discovered that the immune system, if well controlled, provides protection against self-destructive activities. Here we show that in mice with closed head injury, the immune system plays a key role in the spontaneous recovery. Strain-related differences were observed in the ability to harness a T cell-dependent protective mechanism against the effects of the injury. We further show that the trauma-induced deficit could be reduced, both functionally and anatomically, by post-traumatic vaccination with Cop-1, a synthetic copolymer used to treat patients with multiple sclerosis and found (using a different treatment protocol) to effectively counteract the loss of neurons caused by axonal injury or glutamate-induced toxicity. We suggest that a compound such as Cop-1 can be safely developed as a therapeutic vaccine to boost the body's immune repair mechanisms, thereby providing multifactorial protection against the consequences of brain trauma.


Assuntos
Complexo I de Proteína do Envoltório/uso terapêutico , Traumatismos Cranianos Fechados/tratamento farmacológico , Traumatismos Cranianos Fechados/imunologia , Vacinação/métodos , Animais , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Especificidade da Espécie
2.
Philos Trans R Soc Lond B Biol Sci ; 354(1390): 1697-710, 1999 Oct 29.
Artigo em Inglês | MEDLINE | ID: mdl-10603621

RESUMO

This review first addresses several general aspects of the immunotherapy of multiple sclerosis. Next, two approved immunomodulatory treatments, interferon-beta and copolymer-1 (glatiramer acetate), are reviewed in more detail. Finally, other immunosuppressive therapies and experimental strategies are briefly discussed.


Assuntos
Imunoterapia , Esclerose Múltipla/terapia , Complexo I de Proteína do Envoltório/uso terapêutico , Humanos , Imunossupressores/uso terapêutico , Imunoterapia/métodos , Interferons/efeitos adversos , Interferons/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...